



FOR IMMEDIATE DISTRIBUTION

Contact: Erin Mays
313-567-5016
mays@franco.com

Maria Leonhauser
313-567-5080
leonhauser@franco.com

**EaglePicher Corporation Announces Sale
of Pharmaceutical Services to Aptuit**

Biotech and pharmaceutical innovations will remain the focus

Inkster, Mich. September 26, 2006 – EaglePicher Corporation (EaglePicher) today announced that it has entered into an agreement to sell EaglePicher Pharmaceutical Services, LLC (EP Pharmaceuticals) to Aptuit, Inc. The acquisition is expected to close within the next 90 days subject to receipt of regulatory approvals. Terms of the deal were not disclosed.

“EaglePicher continues to improve and invest in its businesses and, in some instances, identify strategic players that will grow a particular business,” said David Treadwell, president and CEO of EaglePicher. “In Aptuit we have found that strategic player. Aptuit’s focus on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovations, as well as its reputation for excellence in compliance and performance ensures that it will further enhance EP Pharmaceuticals’ offerings.”

EaglePicher Pharmaceuticals has supported the cancer research community since 1985. It is a leading producer of active pharmaceutical ingredients and high-potency compounds that are used to produce anti-cancer drugs and other high-potency pharmaceuticals. It has prepared new drug candidates for use in pre-clinical and toxicology studies as well as in clinical trials and commercial use. This process requires specially designed facilities and operating systems to ensure safe handling and prevent cross contaminations with other drugs.

“This acquisition represents a significant milestone for Aptuit as we continually seek to expand our offering and engineer a better drug

development process," said Michael A. Griffith, CEO of Aptuit. "To better serve our customers, we will be making significant investments over the next 18 months to upgrade EaglePicher's production facility in Harrisonville, Missouri, extend its range of capabilities, and improve its regulatory profile."

Aptuit provides a comprehensive suite of drug development services and competencies to more than 450 pharmaceutical and biotechnology companies worldwide. It provides industry-leading consulting drug development consulting and project management, preclinical technologies, analytical chemistries, informatics and information management, and clinical packaging and logistics, all in one package. Currently the company has 12 facilities globally, complemented by a clinical trial distribution network of 27 depots, accessing more than 70 countries worldwide.

Aptuit also assists clients by designing therapy-specific or product-specific programs that compress timelines, maintain quality and reduce the overall costs of commercialization.

EaglePicher Pharmaceutical Services, formerly Midwest Research Institute (MRI), is headquartered in Lenexa, KS. It is a leading producer of active pharmaceutical ingredients and high-potency compounds. In addition to its products, EaglePicher Pharmaceutical provides support in radiolabeling, early-to-late-stage product development, analytical aid and other services. EaglePicher Pharmaceutical employs approximately 60 people and has facilities in Lenexa, Kansas and Harrisonville, Missouri.

EaglePicher Corporation, based in Inkster, Mich., operates businesses in 9 industries: automotive, defense, space, commercial power, nuclear, semi-conductors, filtration, pharmaceuticals, and medical. Its other companies include Hillsdale Automotive, LLC; Wolverine Advanced Materials, LLC; EaglePicher Boron, LLC; EaglePicher Technologies, LLC; EaglePicher Medical Batteries, LLC, and EP Minerals, LLC. For more information, visit www.eaglepicher.com

#